BERKELEY, Calif., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ: ADRO) today announced that
Stephen T. Isaacs, chairman, president and chief executive officer of Aduro, is scheduled to present at the 37th Annual
J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, January 10, 2019 at 11:30 am PST.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the investor
section of Aduro's website at www.aduro.com. The archived webcast will remain available for replay on Aduro’s website for 30
days.
About Aduro
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that are
intended to transform the treatment of challenging diseases. Aduro's technologies, which are designed to harness the body's natural
immune system, are being investigated in cancer indications, autoimmune diseases and have the potential to expand into infectious
diseases. Aduro's STING pathway activator technology is designed to activate the STING receptor in immune cells, which may result
in a potent tumor-specific immune response. ADU-S100 (MIW815) is the first STING pathway activator compound to enter the clinic and
is currently being evaluated in a Phase 1 clinical trial as a single agent and in combination with ipilimumab and in a Phase 1b
combination trial with spartalizumab (PDR001), an investigational anti-PD-1 monoclonal antibody. Aduro's B-select monoclonal
antibody technology, including BION-1301, an anti-APRIL antibody, is comprised of a number of immune modulating assets in research
and development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technologies. For
more information, please visit www.aduro.com.
